中高疾病活动度RA患者是否按达标治疗原则升级治疗?来自RISE注册的研究结果
基于美国风湿病学会RISE注册2016年1月至2017年6月的数据,纳入50,996例符合标准的RA患者,其中27,274例有纵向数据。最常用的疾病活动度评估工具为RAPID3(78.9%)和CDAI(34.2%)。随访期间治疗改变频率较低(35.6%-54.6%),即使RAPID3或CDAI评分为中高疾病活动度者亦然;年龄≥75岁及已接受csDMARDs联合治疗或bDMARDs联合治疗者调整后更不易改变治疗。
要点
- RAPID3和CDAI是最常用的RA疾病活动度评估工具,使用率分别为78.9%和34.2%。
- 随访期间治疗改变频率仅35.6%-54.6%,中高疾病活动度患者亦未充分升级治疗。
- 年龄≥75岁及已用csDMARDs或bDMARDs联合治疗者调整后更少改变治疗。
核心结论
- 使用ACR国家RISE注册数据发现,即使RA患者处于中高疾病活动度,仍有三分之一至三分之二未改变治疗。
- 需要针对患者和提供者的多模式干预,以促进共享决策、目标导向治疗并克服升级治疗的障碍。
研究设计与样本
- 基于RISE注册2016年1月至2017年6月数据的回顾性队列研究。
- 共50,996例符合标准,其中27,274例有纵向数据;索引访视时药物使用分为单药或csDMARDs/bDMARDs联合治疗。
- 结局为12个月内治疗改变;采用混合模型识别与治疗改变相关的因素。
主要发现
- 最常用的活动度评估工具为RAPID3(78.9%)和CDAI(34.2%)。
- 随访期间治疗改变频率较低(35.6%-54.6%),即使按RAPID3或CDAI评分为中高疾病活动度者亦然。
- 年龄≥75岁者调整后更少改变治疗(ORadj 0.63,95%CI 0.50-0.78)。
- 已接受csDMARDs联合治疗者调整后更少改变治疗(ORadj 0.45,95%CI 0.33-0.61)。
- 已接受bDMARDs联合治疗者调整后更少改变治疗(ORadj 0.30,95%CI 0.24-0.38)。
关键数值与推荐
- 原文未报告具体的疾病活动度阈值或治疗升级的推荐条款。
临床怎么用
- 临床中应常规评估RA疾病活动度并依据达标治疗原则及时调整治疗,尤其关注中高活动度患者。
- 对高龄(≥75岁)及已接受联合治疗的患者,需警惕治疗惰性,加强共享决策和目标导向管理。
局限性
- 原文未明确报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite strong recommendations for routine measurement of rheumatoid arthritis (RA) disease activity and associated treatment changes to attain remission/low disease activity, the measurement tools that clinicians use to evaluate RA patients' disease activity and frequency of treatment change have not been well characterized. Therefore, we evaluated different measurement tools that physicians used to assess RA disease activity and associated RA treatment changes. METHODS: Using data from the Rheumatology Informatics System for Effectiveness (RISE) registry from January 2016 through June 2017, and using the following criteria: age ≥18 years, diagnosis of RA (International Classification of Diseases, Ninth and Tenth Revision, codes), ≥2 RISE visits, and ≥1 RA disease activity measure scored in 2016, we classified eligible patients' drug use at the index visit as monotherapy or combination therapy with conventional synthetic (cs) and biologic disease-modifying antirheumatic drugs (bDMARDs). Outcomes include change in treatment over 12 months. Mixed models identified factors associated with treatment change. RESULTS: Among 50,996 eligible patients, 27,274 had longitudinal data. The most commonly used measures were RAPID3 (78.9%) and the Clinical Disease Activity Index (CDAI) (34.2%). The frequency of treatment change during follow-up was relatively low (35.6-54.6%), even for patients with moderate/high disease activity according to RAPID3 or CDAI scores. Older patients (age ≥75 years; adjusted odds ratio [ORadj ] 0.63 [95% confidence interval (95% CI) 0.50-0.78]) and those already receiving combination therapy with csDMARDs (ORadj 0.45 [95% CI 0.33-0.61]) or combination therapy with bDMARDs (ORadj 0.30 [95% CI 0.24-0.38]) were less likely to change RA treatment even after multivariable adjustment. CONCLUSION: Using the American College of Rheumatology's national RISE registry, one- to two-thirds of RA patients failed to change their treatment, even when experiencing moderate/high disease activity. Multimodal interventions directed at both patients and providers are needed to encourage shared decision-making, goal-directed care, and to overcome barriers to treatment escalation.
引用
- Yun H, Chen L, Xie F, et al. Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology. Arthritis Care Res (Hoboken). 2020. PMID: 31566905. doi:10.1002/acr.24083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。